Bobby Bal is a managing director in the firm’s strategic advisory business, with a focus on the biopharmaceutical sector.
Since joining Evercore, Mr. Bal has been involved in numerous strategic transactions, including advising Bristol-Myers Squibb on its acquisitions of Celgene and Mirati Therapeutics, Parexel on its sale to EQT Private Equity and Goldman Sachs Asset Management, Jazz Pharmaceuticals on its acquisition of GW Pharmaceuticals, AstraZeneca on its acquisition of Alexion Pharmaceuticals, Alnylam on its collaboration with Blackstone, and Eli Lilly on its acquisition of Dermira.
In addition, Mr. Bal has completed financing transactions for Aeglea, Apellis Pharmaceuticals and Cerevel Therapeutics.
Prior to joining Evercore, Mr. Bal spent eight years in the M&A group at UBS advising clients across a variety of sectors, including Walgreens on its acquisition of Rite Aid, MPLX on its combination with MarkWest Energy Partners, and NorthStar Realty on the sale of a $1 billion joint venture interest in its healthcare real estate portfolio.
Mr. Bal earned a B.S. in finance from Virginia Tech.